A Study in Participants With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if LY2189265 is effective and safe in reducing
hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants
with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.